Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual addiction treatment platform for alcohol and opioid use disorder, Ann Arbor MI, raised $118M+. Combines medication-assisted treatment with digital coaching.
Workit Health is an Ann Arbor, Michigan-based virtual addiction treatment company founded in 2015 that provides evidence-based treatment for opioid use disorder (OUD) and alcohol use disorder (AUD) through a telehealth platform. The company has raised over $118 million and operates in multiple US states, delivering medication-assisted treatment (MAT) including buprenorphine prescribing alongside behavioral health coaching and peer support — all accessible from a member's smartphone.\n\nWorkit Health's model addresses the primary barriers to addiction treatment: stigma, geographic access, and cost. By delivering care via telehealth, the platform reaches patients in rural areas and communities where addiction specialists are scarce. The company accepts Medicaid in multiple states, making treatment accessible to lower-income patients who are disproportionately impacted by the opioid crisis. Clinicians on the platform conduct initial assessments by video, prescribe medications electronically, and monitor patient progress through regular virtual check-ins and app-based engagement tools.\n\nThe platform includes a structured digital program with skills-based modules covering triggers, coping strategies, and recovery maintenance, delivered alongside clinical care. Workit Health competes with Bicycle Health, Ophelia, and Boulder Care in the virtual MAT market. The company has expanded to serve employers and health plans as well as direct consumers, positioning it as both a consumer-facing addiction recovery resource and a value-based care solution for payers managing high-cost substance use disorder populations.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.